- Home
- CRNX vs HLN Comparison
CRNX vs HLN Comparison
Compare CRNX & HLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRNX
- HLN
- Stock Information
- Founded
- CRNX 2008
- HLN 2022
- Country
- CRNX United States
- HLN United Kingdom
- Employees
- CRNX N/A
- HLN N/A
- Industry
- CRNX Biotechnology: Pharmaceutical Preparations
- HLN Package Goods/Cosmetics
- Sector
- CRNX Health Care
- HLN Consumer Discretionary
- Exchange
- CRNX Nasdaq
- HLN Nasdaq
- Market Cap
- CRNX 2.8B
- HLN 48.2B
- IPO Year
- CRNX 2018
- HLN N/A
- Fundamental
- Price
- CRNX $31.11
- HLN $9.60
- Analyst Decision
- CRNX Strong Buy
- HLN Buy
- Analyst Count
- CRNX 8
- HLN 1
- Target Price
- CRNX $74.86
- HLN $10.95
- AVG Volume (30 Days)
- CRNX 793.9K
- HLN 12.8M
- Earning Date
- CRNX 08-07-2025
- HLN 07-31-2025
- Dividend Yield
- CRNX N/A
- HLN 1.85%
- EPS Growth
- CRNX N/A
- HLN 38.94
- EPS
- CRNX N/A
- HLN 0.20
- Revenue
- CRNX $760,000.00
- HLN $14,062,871,660.00
- Revenue This Year
- CRNX $402.02
- HLN $3.63
- Revenue Next Year
- CRNX $771.03
- HLN $4.37
- P/E Ratio
- CRNX N/A
- HLN $23.95
- Revenue Growth
- CRNX N/A
- HLN N/A
- 52 Week Low
- CRNX $24.10
- HLN $8.80
- 52 Week High
- CRNX $62.53
- HLN $11.42
- Technical
- Relative Strength Index (RSI)
- CRNX 49.76
- HLN 19.49
- Support Level
- CRNX $31.42
- HLN $9.54
- Resistance Level
- CRNX $33.28
- HLN $10.15
- Average True Range (ATR)
- CRNX 1.44
- HLN 0.11
- MACD
- CRNX 0.23
- HLN -0.05
- Stochastic Oscillator
- CRNX 53.79
- HLN 6.18
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
About HLN Haleon plc (Each representing two)
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.